Phase 2, Multicenter, Randomized, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤ 45%) After Myocardial Infarction
Latest Information Update: 21 Mar 2024
At a glance
- Drugs CDR 132L (Primary)
- Indications Heart failure
- Focus Proof of concept; Therapeutic Use
- Acronyms HF-REVERT
- Sponsors Cardior Pharmaceuticals
- 18 Mar 2024 Planned End Date changed from 30 Apr 2025 to 11 Mar 2025.
- 18 Mar 2024 Planned primary completion date changed from 30 Apr 2024 to 4 Sep 2024.
- 18 Mar 2024 Status changed from recruiting to active, no longer recruiting.